返回 Agendas
FDA Enforcement Update: Advertising and Promotion
Session Chair(s)
Philomena McArthur, JD
VP, Global Policies, Procedures & Training, Health Care Compliance & Privacy
Johnson & Johnson International, United States
FDA enforcement actions and policy guidances need to be understood by every company because they reflect FDA's priorities and concerns in regulating advertising and promotion. In this forum, FDA representatives will examine the latest agency enforcement actions and policies and what they mean.
Learning Objective : Describe the latest FDA enforcement actions and policy initiatives in the area of advertising and promotion; Explain what the enforcement actions reflect about FDA policies and priorities.
Speaker(s)
Moderator
Lucy Rose, MBA
Lucy Rose and Associates, United States
President
CDER Point of View
Thomas W. Abrams, MBA, RPh
Former FDA, United States
Retired, Director, Office of Prescription Drug Promotion, OMP, CDER
CBER Point of View
Lisa Stockbridge, PhD
FDA, United States
Branch Chief, Advertising and Promotional Labeling Branch, OCBQ, CBER
CDRH Point of View
Deborah Wolf, JD
FDA, United States
Regulatory Counsel, OPEQ , Regulatory Policy, CDRH